All In Biotech

Drug Trial Radar · NCT05565560

A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Moderate to Severe Plaque Psoriasis

A Phase 3, Multicenter, Open-label, Single-arm Study to Assess the Efficacy and Safety of Apremilast (AMG 407) in Japanese Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis

Last checked: Nov 20, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

21

Actual

Start

Jan 25, 2023

Primary completion

Nov 20, 2025

Study completion Sep 3, 2026

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Oct 4, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the efficacy of apremilast in children and adolescents (ages 6 through 17 years) with moderate to severe plaque psoriasis.

Conditions

  • Plaque Psoriasis

Interventions

  • ApremilastDrug

    Oral tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Achievement of a static Physician Global Assessment (sPGA) score of clear (0) or almost clear (1) with at least 2 points reduction from baseline at Week 16Time frame: Week 16

Locations

29 sites in 1 country. Site status is shown where the registry gives one.

  • Tokyo Medical University Hospital

    Shinjyuku-ku, Japan

  • Nagoya City University Hospital

    Nagoya, Aichi-ken, Japan

  • Fukuoka University Hospital

    Fukuoka, Fukuoka, Japan

  • Hospital of the University of Occupational and Environmental Health, Japan

    Kitakyushu-shi, Fukuoka, Japan

  • Kurume University Hospital

    Kurume-shi, Fukuoka, Japan

  • Fukushima Medical University Hospital

    Fukushima, Fukushima, Japan

  • Gifu University Hospital

    Gifu, Gifu, Japan

  • Gunma University Hospital

    Maebashi, Gunma, Japan

  • Takagi Dermatological Clinic

    Obihiro-shi, Hokkaido, Japan

  • Hokkaido University Hospital

    Sapporo, Hokkaido, Japan

  • Kanazawa Medical University Hospital

    Kahoku-gun, Ishikawa-ken, Japan

  • Takeoka Dermatology Clinic

    Marugame-shi, Kagawa-ken, Japan

  • Takamatsu Red Cross Hospital

    Takamatsu, Kagawa-ken, Japan

  • Saruwatari Dermatology Clinic

    Kagoshima, Kagoshima-ken, Japan

  • Tokai University Hospital

    Isehara-shi, Kanagawa, Japan

  • St Marianna University Hospital

    Kawasaki-shi, Kanagawa, Japan

  • University Hospital Kyoto Prefectural University of Medicine

    Kyoto, Kyoto, Japan

  • Shinshu University Hospital

    Matsumoto-shi, Nagano, Japan

  • Nagasaki University Hospital

    Nagasaki, Nagasaki, Japan

  • University of the Ryukyus Hospital

    Ginowan-shi, Okinawa, Japan

  • Kansai Medical University Hospital

    Hirakata-shi, Osaka, Japan

  • Nippon Life Hospital

    Osaka, Osaka, Japan

  • Kindai University Hospital

    Osakasayama-shi, Osaka, Japan

  • Dokkyo Medical University Hospital

    Shimotsuga-gun, Tochigi, Japan

  • Sugai Dermatology Park Side Clinic

    Utsunomiya, Tochigi, Japan

  • St Lukes International Hospital

    Chuo-ku, Tokyo, Japan

  • Mita Dermatology Clinic

    Minato-ku, Tokyo, Japan

  • Seibo International Catholic Hospital

    Shinjuku-ku, Tokyo, Japan

  • Teikyo University Hospital

    tabashi City, Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.